J E Westlin - JoVE Visualize

Showing results (31-40 of 51) with videos related to

Pageof 6

Sort By:

Cancer|December 24, 1997

The potential of radiolabeled EGF-dextran conjugates in the treatment of urinary bladder carcinomaP Bue, M Márquez, P U Malmström, et al.

Cancer|December 24, 1997

Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphyU Ohrvall, J E Westlin, S Nilsson, et al.

Acta Oncologica (Stockholm, Sweden)|January 1, 1993

Immunotargeting with monoclonal cytokeratin 8 antibodies of human urothelial cancer transplanted to nude miceH Letocha, S Nilsson, A Silén, et al.

Cancer Research|December 1, 1995

Human biodistribution of [111In]diethylenetriaminepentaacetic acid-(DTPA)-D-[Phe1]-octreotide and peroperative detection of endocrine tumorsU Ohrvall, J E Westlin, S Nilsson, et al.

European Urology|November 30, 2000

Intravesical administration of EGF- dextran conjugates in patients with superficial bladder cancerP Bue, A R Holmberg, M Márquez, et al.

Medical Oncology (Northwood, London, England)|May 25, 2002

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogsM L Fjällskog, A Sundin, J E Westlin, et al.

Cancer Research|December 1, 1995

Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markersK M Kälkner, E T Janson, S Nilsson, et al.

Acta Oncologica (Stockholm, Sweden)|June 25, 1999

Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effectsE Tiensuu Janson, B Eriksson, K Oberg, et al.

In Vivo (Athens, Greece)|January 14, 1998

PET with hydroxytryptophan as tracer in hormone-refractory prostatic adenocarcinoma: evaluation of decarboxylation in vivoK M Kälkner, S Nilsson, M Bergström, et al.

Acta Oncologica (Stockholm, Sweden)|June 25, 1999

Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetryM Lubberink, H Lundqvist, J E Westlin, et al.

Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:

Pageof 6

Cancer|December 24, 1997

The potential of radiolabeled EGF-dextran conjugates in the treatment of urinary bladder carcinomaP Bue, M Márquez, P U Malmström, et al.

Cancer|December 24, 1997

Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphyU Ohrvall, J E Westlin, S Nilsson, et al.

Acta Oncologica (Stockholm, Sweden)|January 1, 1993

Immunotargeting with monoclonal cytokeratin 8 antibodies of human urothelial cancer transplanted to nude miceH Letocha, S Nilsson, A Silén, et al.

Cancer Research|December 1, 1995

Human biodistribution of [111In]diethylenetriaminepentaacetic acid-(DTPA)-D-[Phe1]-octreotide and peroperative detection of endocrine tumorsU Ohrvall, J E Westlin, S Nilsson, et al.

European Urology|November 30, 2000

Intravesical administration of EGF- dextran conjugates in patients with superficial bladder cancerP Bue, A R Holmberg, M Márquez, et al.

Medical Oncology (Northwood, London, England)|May 25, 2002

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogsM L Fjällskog, A Sundin, J E Westlin, et al.

Cancer Research|December 1, 1995

Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markersK M Kälkner, E T Janson, S Nilsson, et al.

Acta Oncologica (Stockholm, Sweden)|June 25, 1999

Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effectsE Tiensuu Janson, B Eriksson, K Oberg, et al.

In Vivo (Athens, Greece)|January 14, 1998

PET with hydroxytryptophan as tracer in hormone-refractory prostatic adenocarcinoma: evaluation of decarboxylation in vivoK M Kälkner, S Nilsson, M Bergström, et al.

Acta Oncologica (Stockholm, Sweden)|June 25, 1999

Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetryM Lubberink, H Lundqvist, J E Westlin, et al.

Pageof 6